Buy & Sell Applovin Corporation (APP) – Applovin Corporation Price Today
Aura AI Summary
Key Stats
- $164.84BMarket Cap
- TechnologySector
- -28.06%3M Drawdown
- $165.60BEnterprise Value
- -Dividend Yield
- 94% Buy | 6% SellTrading Activity
- 11 daysTypical Hold Time
Applovin Corporation (APP) is currently valued at a market capitalization of $164.84B, with an enterprise value of $165.60B. Over the past 52 weeks, Applovin Corporation has traded between a low of $324.7 and a high of $733.6, highlighting its annual price range. Over the past three months, Applovin Corporation has recorded a drawdown of -28.06%, reflecting recent price volatility. On average, investors hold Applovin Corporation for approximately 11 days, indicating typical investor behavior on the platform.
About Applovin Corporation
AppLovin provides a software platform for mobile app developers to market, monetize, and analyze their apps. Its AI-powered tools help developers grow their business by connecting them with global advertising networks.
Most Recent News
Semiconductor recovery driven by supply constraints and pricing, not unit growth, led by memory chips for AI.
The semiconductor industry recovery is now led by memory chip pricing increases due to supply constraints rather than unit shipment growth. After a severe downturn in 2022, memory manufacturers cut capital expenditures and limited capacity expansion,...
Megan Holdings receives Nasdaq notice for falling below $1 minimum bid price, must regain compliance by Nov 2026.
Megan Holdings Limited announced it received a Nasdaq notification for not meeting the minimum bid price of $1 per share, with its shares trading below this threshold for 30 consecutive business days. The company has 180 days, until November 9, 2026,...
Absci insider buys shares amid financial challenges and positive clinical trial progress
A director at Absci purchased 37,453 shares, showing confidence despite the company's Q1 2026 revenue missing estimates by 90%. Absci reported a smaller-than-expected loss and progress in its ABS-201 clinical trial with positive safety data. The insi...